{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inflammation+%28II%29&page=2", "query": { "intervention": "Inflammation (II)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inflammation+%28II%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T05:26:50.478Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05363891", "title": "Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Natrunix", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XBiotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 243, "start_date": "2023-08-08", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 26, "location_summary": "Covina, California • Encino, California • Rancho Mirage, California + 19 more", "locations": [ { "city": "Covina", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Tujunga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05363891" }, { "nct_id": "NCT04747912", "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia", "ph+ Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Inotuzumab ozogamicin", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Purinethol (6-Mercaptopurine)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-03-02", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04747912" }, { "nct_id": "NCT06445192", "title": "Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Carcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Exercise Counseling", "type": "OTHER" }, { "name": "Exercise Intervention", "type": "OTHER" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Physical Performance Testing", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Telemedicine", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 65, "start_date": "2023-11-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445192" }, { "nct_id": "NCT01456208", "title": "Genetic Mechanisms in Human Hypertension", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Para-aminohippuric Acid", "type": "DRUG" }, { "name": "Angiotensin II", "type": "DRUG" }, { "name": "Norepinephrine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "1999-10", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2021-05-12", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01456208" }, { "nct_id": "NCT05384132", "title": "Novel Dental Gel as an Adjunct to Scaling and Root Planing", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Periodontal Diseases", "Gingival Diseases", "Gingival Pocket", "Gum Bleed", "Plaque, Dental" ], "interventions": [ { "name": "SRP + Livfresh Dental Gel", "type": "OTHER" }, { "name": "SRP + standard flouride dentifrice", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 76, "start_date": "2022-10-14", "completion_date": "2028-10-30", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05384132" }, { "nct_id": "NCT00962949", "title": "The Renin-Aldosterone Axis in Postural Tachycardia Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Postural Orthostatic Tachycardia Syndrome (POTS)" ], "interventions": [ { "name": "Angiotensin II", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 28, "start_date": "2009-04", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00962949" }, { "nct_id": "NCT05193370", "title": "Angiotensin II vs. Vasopressin in Septic Shock", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Septic Shock" ], "interventions": [ { "name": "Angiotensin II", "type": "DRUG" }, { "name": "Vasopressin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-01-03", "completion_date": "2022-11-30", "has_results": false, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT05193370" }, { "nct_id": "NCT00579020", "title": "A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Corneal Infiltrates" ], "interventions": [ { "name": "Moxifloxacin/dexamethasone phosphate ophthalmic solution", "type": "DRUG" }, { "name": "Moxifloxacin ophthalmic solution 0.5%", "type": "DRUG" }, { "name": "Dexamethasone phosphate solution, 0.1%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 144, "start_date": "2007-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2012-12-05", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 1, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579020" }, { "nct_id": "NCT02179008", "title": "Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Open-angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "DE-117 Low Dose ophthalmic solution", "type": "DRUG" }, { "name": "DE-117 Low/Middle Dose ophthalmic solution", "type": "DRUG" }, { "name": "DE-117 Middle Dose ophthalmic solution", "type": "DRUG" }, { "name": "DE-117 Middle/High Dose ophthalmic solution", "type": "DRUG" }, { "name": "DE-117 High Dose ophthalmic solution", "type": "DRUG" }, { "name": "latanoprost ophthalmic solution 0.005%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2014-06", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2018-04-18", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 14, "location_summary": "Chandler, Arizona • Artesia, California • Glendale, California + 11 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Artesia", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02179008" }, { "nct_id": "NCT02099656", "title": "A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Inhaled corticposteroids (ICS)", "type": "DRUG" }, { "name": "Second Asthma Controller Medication", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 64, "start_date": "2014-11-06", "completion_date": "2016-10-13", "has_results": false, "last_update_posted_date": "2017-09-06", "last_synced_at": "2026-09-25T05:26:50.478Z", "location_count": 16, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Deerfield Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02099656" } ] }